Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status

Conclusion: Survival benefit of nivolumab in patients with NSCLC with poor PS, especially 3 or 4, was not confirmed. Further studies with larger numbers of patients are required to confirm our results.

Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Hideyuki Katsura, Yukio Suga, Tomoyuki Araya, Toshiyuki Kita, Taro Yoneda, Nobuyoshi Tanaka, Ayumi Kawabata, Sotoki Ishita, Hiroki Mase Tags: Research Paper Source Type: research